Kimberly-Clark stock (US4943681035): EU clears $3.4B tissue JV with Suzano

The European Union has approved Suzano's $3.4 billion joint venture for a 51% stake in Kimberly-Clark's international tissue business, including brands like Kleenex, paving the way for the deal announced last year.

Kimberly-Clark Corporation saw a key regulatory milestone on May 11, 2026, when the European Commission unconditionally approved a $3.4 billion joint venture with Brazil's Suzano. Suzano will acquire a 51% stake in Kimberly-Clark's international tissue operations, which include popular brands such as Kleenex, Scott, and Cottonelle across 22 facilities in 14 countries. The approval confirms no significant competition concerns in the EU, according to Morningstar as of 05/12/2026.

The deal, first announced in June 2025, remains under review by the UK's Competition and Markets Authority, with a decision expected by May 28, 2026, per Global Banking & Finance as of 05/11/2026. This development is relevant for US investors as Kimberly-Clark (NYSE: KMB) maintains significant exposure to global consumer goods markets, with the tissue segment contributing to its diversified portfolio.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Kimberly-Clark Corporation
• Sector/industry: Consumer Staples / Personal Care & Household Products
• Headquarters/country: Irving, Texas, USA
• Core markets: North America, Europe, Latin America, Asia
• Key revenue drivers: Tissue, personal care products
• Home exchange/listing venue: NYSE (KMB)
• Trading currency: USD

Kimberly-Clark: core business model

Kimberly-Clark Corporation is a leading global personal care company that manufactures and markets a wide range of products including tissues, wipes, diapers, and feminine care items. The company operates through segments such as Personal Care, Consumer Tissue, and K-C Professional, serving consumers and businesses worldwide. In recent quarters, it reported quarterly revenue of $4.16 billion, up 2.7% year-over-year, with a net margin of 12.80% and return on equity of 152.79% as of its latest filing, according to MarketBeat as of 05/12/2026.

For US investors, Kimberly-Clark's strong brand portfolio and consistent dividend history make it a staple in consumer staples portfolios, with shares listed on the NYSE under ticker KMB.

Main revenue and product drivers for Kimberly-Clark

Key revenue streams come from iconic brands like Huggies diapers, Kotex feminine care, and Kleenex tissues, which drive sales in both developed and emerging markets. The international tissue business, now subject to the Suzano JV, represents a significant portion of operations outside North America. This segment benefits from global demand for hygiene products, bolstered by Kimberly-Clark's innovation in sustainable materials.

In its most recent quarter, revenue growth was supported by volume increases and pricing strategies, highlighting resilience amid inflationary pressures relevant to US market dynamics.

Industry trends and competitive position

The global tissue and personal care industry faces headwinds from raw material costs like pulp, but benefits from steady demand as essential goods. Kimberly-Clark competes with Procter & Gamble and Essity, maintaining a strong position through brand loyalty and supply chain efficiencies. The Suzano JV could enhance pulp access, potentially lowering costs long-term.

Why Kimberly-Clark matters for US investors

Listed on the NYSE, Kimberly-Clark offers US investors exposure to defensive consumer staples with global reach, including meaningful US market share in diapers and tissues. Its products are household names, providing stability during economic volatility affecting the broader US equity market.

Conclusion

The EU's approval of the Suzano joint venture marks progress for Kimberly-Clark's strategic portfolio optimization, potentially streamlining its international tissue operations. While UK review pendings add some uncertainty, the company's solid fundamentals and brand strength continue to underpin its market position. Investors will watch for completion of the deal and upcoming earnings for further insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.